comprehensive -WSS

comprehensive

author：leisure time 2025-09-06 03:50:35 - browse：4

A photograph of someone preparing small petri dishes, each holding several 1-7 day old embryos, for cells to be extracted from each embryo to test for viability at an in vitro fertilization lab — In vitro fertilization lab staff prepare small petri dishes, each holding embryos. (This sample image doesn't necessarily show embryos grown in media from CooperSurgical, a supply giant now facing lawsuits.) Michael Wyke/AP

Patients from all over the country are filing lawsuits against medical supply giant CooperSurgical, alleging that fluid the company sent to in vitro fertilization clinics destroyed their embryos.

The fluid, called culture media, is filled with nutrients that allow embryos to develop enough to ultimately be implanted into a uterus. CooperSurgical acknowledged that the batch of fluid may have stunted embryo growth in a product recall notice, but it hasn’t disclosed exactly what went wrong. Lawsuits claim the media lacked magnesium, a key nutrient, while a Cooper representative told STAT the cause is still under investigation.

The recall could be a one-off manufacturing fluke. But the debacle, and the uncertainty around the problems with the fluid, sheds light on a larger problem: IVF doctors rarely know the exact composition of culture media in the first place. The Food and Drug Administration asks manufacturers for a list of materials before the media goes on the market, an FDA spokesperson told STAT. Companies will sometimes give clinics this information voluntarily, along with required labeling information like mouse embryo data, instructions for use, and warnings. But the FDA doesn’t require companies to list the ingredients or their proportions publicly.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Merck, Daiichi strike cancer drug pact worth up to $22 billion

WSS

Medicare Advantage's lean provider networks lead CMS complaints

Results on Novartis prostate cancer therapy could expand its use

STAT wants to know your pick for a great summer read or listen

STAT Readout Newsletter: Biotech news today

'Little Tech' descents on D.C., wanting a say in how AI is regulated

ASCO Takeaways: Winners, snoozers, and the art of cancer care

hotspot

comprehensive

hotspot

DIEP, the 'gold standard' of breast reconstruction, is under threat

The problems with dementia villages

How to save PrEP access — and even expand it

Smaller biotechs seek to piggyback on weight loss drug boom

Duchenne breakthrough therapy leaves behind pioneering families

Illumina board agrees to spin off Grail, as divestment plans proceed

Supreme Court strikes down use of affirmative action

Health tech investors get more selective as pandemic boom fades

Alkermes shareholders re

Smaller biotechs seek to piggyback on weight loss drug boom

focus

Finland to offer bird flu vaccine to select groups of people, a possible global first

STAT Readout Newsletter: Biotech news today

UnitedHealth, Optum discontinue NaviHealth name

Roche drug slashes death risk in early

Questions loom on AstraZeneca cancer drug as safety concerns ebb

STAT Summit: Ending the crisis of Black deaths in the U.S.

Wikipedia

leisure time

Wikipedia

explore